Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
7.10
-0.11 (-1.53%)
Apr 8, 2026, 11:28 AM EDT - Market open
Karyopharm Therapeutics Employees
Karyopharm Therapeutics had 228 employees as of December 31, 2025. The number of employees decreased by 51 or -18.28% compared to the previous year.
Employees
228
Change (1Y)
-51
Growth (1Y)
-18.28%
Revenue / Employee
$640,645
Profits / Employee
-$859,820
Market Cap
160.06M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 228 | -51 | -18.28% |
| Dec 31, 2024 | 279 | -46 | -14.15% |
| Dec 31, 2023 | 325 | -60 | -15.58% |
| Dec 31, 2022 | 385 | -57 | -12.90% |
| Dec 31, 2021 | 442 | 10 | 2.31% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sangamo Therapeutics | 183 |
| Innate Pharma | 163 |
| Fate Therapeutics | 161 |
| Agenus | 81 |
| Equillium | 35 |
| Spero Therapeutics | 25 |
| Black Diamond Therapeutics | 21 |
KPTI News
- 14 days ago - Karyopharm Therapeutics Falls As Pivotal Trial Hits Spleen Goal But Misses Symptom Mark - Benzinga
- 15 days ago - Karyopharm Therapeutics' blood cancer drug meets one of two main goals in study - Reuters
- 15 days ago - Karyopharm Announces $30 Million Private Placement with RA Capital - PRNewsWire
- 15 days ago - Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction - PRNewsWire
- 5 weeks ago - Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 7 weeks ago - Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress - PRNewsWire
- 2 months ago - Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 - PRNewsWire
- 3 months ago - Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026 - PRNewsWire